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CASE REPORT

Thrombocytapheresis for acquired von Willebrand
syndrome in a patient with essential thrombocythemia
and recent multivisceral transplantation
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Abstract
Background: Essential thrombocythemia (ET) is associated with increased
risk of bleeding secondary to acquired von Willebrand syndrome (AVWS).
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Bleeding in ET requires urgent platelet reduction by cytoreductive therapy
such as hydroxyurea or thrombocytapheresis. We report on the efficacy and
safety of thrombocytapheresis in managing AVWS in a patient with ET and
multivisceral transplantation.
Case report: The patient was a 51-year-old female who underwent multivisceral transplantation. Her postoperative course was complicated by bleeding
from oral cavity, IV lines, gastrointestinal and upper respiratory tracts as well
as vaginal bleeding, which coincided with ET flare with a platelet count of
1512  109/L. Coagulation studies including von Willebrand factor (vWF) antigen and activity, vWF propeptide antigen, and vWF multimer analysis were
consistent with AVWS. Hydroxyurea was initiated. However, due to major
bleeding, rapidly increasing platelet count, and uncertainty of response to
hydroxyurea being given through the enteral tube, thrombocytapheresis was
initiated for rapid platelet reduction. The patient tolerated the procedure well.
Platelet count was reduced from 1636  109/L to 275  109/L with rapid cessation of bleeding. The patient's condition stabilized over the next few days; however, bleeding recurred with increasing platelet count, which required a
second thrombocytapheresis 8 days after the first one. The patient was
maintained on hydroxyurea 500 mg twice/day. At 11-month follow-up, she
had a normal platelet count and no recurrence of bleeding.
Discussion: Thrombocytapheresis is safe and efficient in managing postoperative bleeding due to ET/AVWS in solid organ transplant patients. The procedure can be an adjunct to bridging therapy before response to hydroxyurea is
achieved.

Previous Presentation: This work was presented, in part, at the American Society for Apheresis Annual Meeting, May 12–15, 2021.
Reprints will not be available from the author.
Transfusion. 2021;1–4.
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1 | INTRODUCTION
Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm that primarily involves the megakaryocytic lineage.1 It is characterized by sustained increase in
platelet count (≥ 450  109/L) and increased number of
mature megakaryocytes in the bone marrow.1,2 ET is
associated with an increased risk of thrombosis and
bleeding. Bleeding in patients with ET can be associated
with acquired von Willebrand syndrome (AVWS).3
AVWS is characterized by clinical features and laboratory
findings similar to those seen in inherited von Willebrand
disease (vWD).4 Various mechanisms have been implicated in AVWS, with the majority leading to increased
clearance or degradation of circulating von Willebrand
factor resulting in selective loss of vWF high molecular
weight (HMW) multimers.5
Bleeding in ET requires urgent platelet reduction by
platelet cytoreductive agents such as hydroxyurea or by
thrombocytapheresis, which is considered category II
indication in managing symptomatic thrombocytosis
according to the 2019 American Society for Apheresis
(ASFA) guidelines.5-7 We report on the efficacy and safety
of thrombocytapheresis in managing AVWS in a patient
with ET and recent multivisceral transplantation. To the
best of our knowledge, there are no published reports on
thrombocytapheresis in this setting.

2 | CASE PRESENTATION
Our patient was a 51-year-old African American female
who recently underwent multivisceral organ transplantation that involved the stomach, small bowel, pancreas,
and liver. The patient's medical history was significant
for JAK2-positive ET, liver cirrhosis secondary to Budd–
Chiari syndrome, heparin-induced thrombocytopenia,
and multiple thromboses. The patient was maintained on
aspirin and coumadin until surgical admission for transplantation. She received bridging parenteral anticoagulation perioperatively with bivalirudin that was
held a day before surgery and was restarted 5 days postsurgery. Her postoperative course was complicated by
fungal infection and bleeding, requiring exploring laparotomy and partial gastric resection. She subsequently
developed bleeding from oral cavity, oozing from IV
lines, gastrointestinal and upper respiratory tracts as well

as vaginal bleeding, which coincided with ET flare.
Complete blood count at the time of bleeding showed
WBC of 38,700/uL, hemoglobin value of 7.2 g/dL, and
platelet count of 1512  109/L. Basic coagulation studies
revealed increased activated partial thromboplastin time
of 37 sec (22.0–36.0 sec), mildly increased prothrombin
time of 14.6 sec (12.1–14.5 sec), normal fibrinogen level
of 425 mg/dL (200–450 mg/dL), and increased D dimers
of 12.44 ug/ml (<0.51 ug/ml). vWD evaluation during the
ET flare showed increased Factor VIII activity of 314%
(50–150%), increased von Willebrand factor (vWF)
antigen of 317% (50–150%), low vWF activity of 50% (51–
215%), very low vWF activity/antigen ratio of 0.16,
normal vWF propeptide antigen and absence of HMW
multimers on vWF multimer analysis. This profile was
consistent with AVWS.
Following this major bleeding event, bivalirudin was
discontinued as well as aspirin. Antifibrinolytic therapy
with IV tranexamic acid was initiated with modest clinical improvement. Due to previous history of extensive
thrombosis and hypercoagulable state, fondaparinux at a
prophylactic dose of 2.5 mg was initiated once hemostasis
was achieved but was stopped again because of recurrent
bleeding. Cytoreductive therapy with hydroxyurea was
initiated at a starting dose of 15–20 mg/kg/day and was
adjusted with a goal to decrease platelet counts below
450  109/L. Due to major bleeding, rapidly increasing
platelet count, and uncertainty of response to hydroxyurea being given through the enteral tube, thrombocytapheresis was initiated for rapid reduction of platelets.
After obtaining informed consent, thrombocytapheresis
was performed using the Spectra Optia (Terumo BCT,
Lakewood, CO) processing 2.0 total blood volumes
through a temporary femoral central venous catheter.
Manufacturer's recommendations were followed to perform therapeutic thrombocytapheresis. Anticoagulant citrate dextrose solution, solution A (ACD-A) was used with
an inlet:AC ratio 10:1. A total of 4 g of IV calcium gluconate was infused throughout the procedure. The patient
tolerated the procedure well. Platelet count was reduced
from 1636  109/L to 275  109/L with rapid cessation of
bleeding. A second thrombocytapheresis was performed
8 days following the first session due to increased platelet
count, recurrent gastrointestinal bleeding, and worsening
anemia; the procedure was tolerated well, and platelet
count was reduced from 1035  109/L to 266  109/L
(Figure 1). The patient was maintained on hydroxyurea
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F I G U R E 1 Platelet count changes with clinical symptoms and therapeutic course. The horizontal axis represents follow-up time in days
from transplant. The vertical scale represents platelet count

500 mg twice a day. She had another transient increase
in her platelet count 1 week after the second procedure
without evidence of bleeding. At 11-month follow-up, she
had a normal platelet count and no recurrence of
bleeding.

3 | DISCUSSION
AVWS is defined as any qualitative, structural, or functional disorder of vWF that is not inherited and is often
associated with bleeding risk.8 The pathogenesis of
AVWS involves multiple proposed mechanisms including
development of antibodies to vWF, increased plasma
clearance of vWF by cell adsorption, shear stress, or
increased proteolysis.9, 10 AVWS is recognized in the
setting of background disease processes, which include
lymphoproliferative, myeloproliferative, cardiovascular,
and immunological disorders.11 Lymphoproliferative
disorders account for a substantial percentage of AVWS
cases11; only few studies have explored the association of
myeloproliferative neoplasms with AVWS. In a retrospective study by Mital and colleagues on 170 patients regarding the prevalence of AVWS in patients with ET showed
that AVWS was found in 34 (20%) patients indicating that
a significant population of ET patients may develop this
syndrome.12 Predictors of AVWS in patients with ET
included younger age, higher hemoglobin levels, and the

presence of JAK2V617F mutation. The group recommended the need to screen patients with ET and signs
of bleeding for AVWS, irrespective of the platelet count.12
Patients with AVWS demonstrate a bleeding diathesis
usually late in life without any past or family history of
bleeding. The diagnosis is based on clinical findings and
laboratory tests used to diagnose inherited vWD.13 Samples show a marked decrease in vWF activity with
normal or mildly decreased vWF antigen, and absence
of HMW vWF multimers similar to type 2A or 2B
vWD.14, 15 Plasma vWF propeptide, which correlates with
vWF biosynthesis, will be normal as AVWS is characterized by increased clearance of vWF only.16
The aims of treatment in AVWS patients are to rapidly control or prevent acute bleeding and achieve a stable remission of the syndrome. Treatment of the
underlying associated condition is the only potential cure
for AVWS.4 Bleeding risk in patients with ET increases
significantly when the platelet count is >1000–
1500  109/L. Rapid control of bleeding can be achieved
with different medications including cytoreductive
agents, desmopressin (DDAVP), vWF concentrates, or
antifibrinolytic agents.4 Thrombocytapheresis is considered category II indication (i.e., second-line therapy) with
Grade 2C recommendation (weak recommendation, low
quality or very low quality evidence) in managing symptomatic thrombocytosis according to the 2019 American
Society for Apheresis (ASFA) guidelines.7 It has been
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utilized for cytoreduction of patients at increased risk of
major bleeding when hydroxyurea is contraindicated or
when rapid reduction is necessary.7, 17, 18
The paradox of bleeding in a patient with ET and
high platelet count is a clinical challenge, and accurate
management of AVWS is a matter of clinical judgment
among physicians. The suspicion for AVWS was very
high in our patient; she had a history of ET without previous personal or family history of bleeding. She
manifested with bleeding when her platelet count was
above 1000  10/L. The diagnosis of AVWS was confirmed with vWD laboratory testing, which revealed a
markedly decreased ratio of vWF activity/antigen,
absence of HMW vWF multimers, and normal vWF propeptide. Thrombocytapheresis was urgent in our case
because of recurrent major bleeding, rapidly increasing
platelet count, and the very uncertainty of response to
hydroxyurea being given through the enteral tube.
Thrombocytapheresis was very efficient in reducing the
platelet count, thus achieving rapid cessation of bleeding.
A second procedure was performed 8 days after the first
session with good tolerance and efficiency. No adverse
event was recorded during the two procedures.

4 | C ON C L U S I ON
Thrombocytapheresis is safe and efficient in managing
postoperative bleeding due to ET/AVWS in solid organ
transplant patients. The procedure can be an adjunct to
bridging therapy before response to cytoreductive therapy
is achieved.
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